Blog
RSS FeedPosted by Michael Wonder on 06 Jun 2022
Novavax faces high stakes FDA review this week that will decide the fate of its COVID vaccine in the U.S.
6 June 2022 - If they endorse the vaccine, the FDA will almost certainly authorise the shot for adults in the ...
Posted by Michael Wonder on 06 Jun 2022
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
6 June 2022 - Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients ...
Posted by Michael Wonder on 02 Jun 2022
Pfizer asks FDA to authorise COVID-19 vaccine for youngest kids
1 June 2022 - Pfizer and BioNTech announced Wednesday that they have completed their submission requesting emergency use authorisation from ...
Posted by Michael Wonder on 02 Jun 2022
COVID-19 vaccine weekly safety report (2 June 2022)
2 June 2022 - To 29 May 2022, the TGA has received 573 reports which have been assessed as likely to ...
Posted by Michael Wonder on 02 Jun 2022
Health Canada OKs Pfizer COVID-19 booster shot for teens ages 16 and 17
1 June 2022 - Canada on Wednesday authorised a single booster shot of Pfizer and partner BioNTech’s COVID-19 vaccine for ...
Posted by Michael Wonder on 01 Jun 2022
VBI Vaccines announces UK MHRA marketing authorisation for PreHevbri, a 3 antigen adult hepatitis B vaccine
1 June 2022 - Approval follows the European Commission’s marketing authorisation, granted in April 2022. ...
Posted by Michael Wonder on 29 May 2022
ATAGI update following weekly COVID-19 meeting (25 May 2022)
27 May 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 25 ...
Posted by Michael Wonder on 26 May 2022
COVID-19 vaccine weekly safety report (26 May 2022)
26 May 2022 - To 22 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 25 May 2022
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
25 May 2022 - The Australian Technical Advisory Group on Immunisation (ATAGI) have expanded their recommendations on the use of additional ...
Posted by Michael Wonder on 24 May 2022
Blue Lake Biotechnology announces FDA fast track designation for BLB-201 intranasal RSV vaccine
24 May 2022 - Blue Lake Biotechnology today announced that the U.S. FDA has granted fast track designation for BLB-201, an ...
Posted by Michael Wonder on 23 May 2022
ATAGI update following weekly COVID-19 meeting (18 May 2022)
23 May 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 18 ...
Posted by Michael Wonder on 23 May 2022
Vaxzevria approved in the EU as third dose booster against COVID-19
23 May 2022 - Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU approved ...
Posted by Michael Wonder on 19 May 2022
EMA accepts filing of marketing authorisation application for Valneva’s inactivated COVID-19 vaccine candidate
19 May 2022 - 2022 – Valneva today confirmed that the EMA has accepted the filing of a marketing authorisation ...
Posted by Michael Wonder on 19 May 2022
COVID-19 vaccine weekly safety report (19 May 2022)
19 May 2022 - To 15 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 17 May 2022
FDA expands eligibility for Pfizer-BioNTech COVID-19 vaccine booster dose to children 5 through 11 years
17 May 2022 - Today, the U.S. FDA amended the emergency use authorisation for the Pfizer-BioNTech COVID-19 vaccine, authorising the use ...